Research.Patient.info
Non-Transfusion Dependent Beta-Thalassemia (NTDT) research hub
2 indexed studies · 1 currently recruiting
- recruitingPHASE2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
This study is testing a new under-the-skin injection, REGN7999, for adults with non-transfusion dependent beta-thalassemia and too much iron. It aims to check if the drug is safe, works well, and lowers iron levels, using MRI scans to measure iron.
United States · Georgia · Greece - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (An Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia.
This study is testing a new medicine (REGN7999) for adults with a gentle type of beta-thalassemia (NTDT) and too much iron in their body. It aims to see if the medicine can reduce iron levels and improve health, compared to a placebo, with minimal side effects.
Greece · Italy